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Abstract Owing to their massive use, Staphylococcus
epidermidis has recently developed significant resistance to
several antibiotics, and became one of the leading causes of
hospital-acquired infections. Current antibiotics are typi-
cally ineffective in the eradication of bacteria in biofilm-
associated persistent infections. Accordingly, the paucity
of effective treatment against cells in this mode of growth
is a key factor that potentiates the need for new agents
active in the prevention or eradication of biofilms. Dapto-
mycin and linezolid belong to the novel antibiotic therapies
that are active against gram-positive cocci. On the other
hand, rifampicin has been shown to be one of the most
potent, prevalent antibiotics against S. epidermidis bio-
films. Therefore, the main aim of this study was to study
the susceptibility of S. epidermidis biofilm cells to the two
newer antimicrobial agents previously mentioned, and
compare the results obtained with the antimicrobial effect
of rifampicin, widely used in the prevention/treatment of
indwelling medical device infections. To this end the in
vitro activities of daptomycin, linezolid, and rifampicin on
S. epidermidis biofilms were accessed, using these antibi-
otics at MIC and peak serum concentrations. The results
demonstrated that at MIC concentration, rifampicin was the
most effective antibiotic tested. At peak serum concentra-
tion, both strains demonstrated similar susceptibility to
rifampicin and daptomycin, with colony-forming units
(CFUs) reductions of approximately 3–4 log10, with a
slightly lower response to linezolid, which was also more
strain dependent. However, considering all the parameters
studied, daptomycin was considered the most effective
antibiotic tested, demonstrating an excellent in vitro
activity against S. epidermidis biofilm cells. In conclusion,
this antibiotic can be strongly considered as an acceptable
therapeutic option for S. epidermidis biofilm-associated
infections and can represent a potential alternative to rif-
ampicin in serious infections where rifampicin resistance
becomes prevalent.
Introduction
Staphylococcus epidermidis, which are part of the normal
microflora of the human skin and mucous membranes, have
attracted considerable attention more recently as dangerous
nosocomial pathogens [1]. This bacterium has the ability to
adhere to implanted medical devices or damaged tissues,
and form biofilms, which become the focus of persistent
infections [2] and causes devastating complications which
prolong disease and result in higher-morbidity and -mor-
tality, especially in immuno-compromised patients [3].
Since bacteria in biofilm demonstrated a greater capacity to
evade clearance by the host defences and by antimicrobial
chemotherapy, this feature is recognized as a key virulence
determinant of this pathogen [1, 2]. In addition to the
reduced susceptibility of bacteria to antimicrobial agents
when in this mode of life, the increasing occurence of
resistance has created a need for the development of new
antimicrobial agents [4].
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Daptomycin and linezolid are newer antimicrobial agents
that are active against gram-positive cocci [5, 6]. Dapto-
mycin, a lipopeptide, has a spectrum of activity very similar
to vancomycin [6]. Linezolid, has excellent activity against
most staphylococci in systemic infections; nevertheless,
resistance has begun to emerge [7–9]. Although rifampicin
cannot be used as a single agent to treat infections because of
the rapid selection of resistant mutants [10, 11], it has proven
to be the most efficient antibiotic against S. epidermidis
biofilm-associated infections [12, 13].
The aim of the present study was to evaluate the in vitro
activity of two antibiotics of new generation, daptomycin
and linezolid, against S. epidermidis biofilms and compare
the results with the response to rifampicin, the most effi-
cient of the traditional antibiotics for this purpose.
Materials and Methods
Bacterial Strains and Growth Conditions
In this study, two previously well-characterized biofilm-
producing S. epidermidis strains were used: 9142 and 1457
[14]. These strains are clinical isolates and were stored at
-80C. Tryptic soy broth (TSB) and tryptic soy agar
(TSA) were prepared according to the manufacturer’s
instructions. All strains were inoculated into 15 ml of TSB
from TSA plates not older than 2 days and grown for 18
(±2) h at 37C in an orbital shaker at 130 rpm. Cells were
harvested by centrifugation (for 10 min at 9,5009g and
4C), resuspended in TSB, and the suspension was adjusted
to an optical density (640 nm) equivalent to 1 9 109 cells
ml-1 before being used in the subsequent assays. Each
stock solution of daptomycin (with calcium supplementa-
tion at 50 mg l-1) [15, 16] and rifampicin was prepared in
methanol. It was confirmed that methanol, at the concen-
tration used, had no effect on the growth of the S. epide-
rmidis strains studied. The stock solution of linezolid was
prepared in Milli-Q water.
Minimum Inhibitory Concentration (MIC)
The MIC was determined by the microbroth dilution
methodology, according to the CLSI. MIC determination
of the tested agents and for both S. epidermidis strains
(9142 and 1457) was performed by the serial twofold
dilution method at concentrations ranging from 0.007 to
16 lg ml-1, using 96-well tissue culture plates (Sarstedt,
Newton, NC, USA). The antibiotics were first diluted to the
highest concentration to be tested, and then serial twofold
dilutions were made. The final cell concentration used was
approximately 5 9 105 cells ml-1. Plates were incubated
for 24 h at 37C on an orbital shaker (130 rpm). After
incubation, the MIC was determined as the lowest con-
centration required to inhibit bacterial growth.
The controls were the cells which were not exposed to
the antimicrobial agents tested. All the experiments were
carried out in triplicate and repeated three times.
Biofilm Formation and Susceptibility Tests
Biofilms were formed in 96-well tissue culture plates
(Sarstedt, Newton, NC, USA) containing 200 ll of
S. epidermidis cell suspension (1 9 106 cells ml-1) in
TSB, supplemented with 0.25% of glucose per well to
promote biofilm formation [12]. Plates were incubated at
37C with orbital shaking at 130 rpm for 24 h. At the end,
the planktonic cells were gently removed from the biofilm-
containing well by pippeting off the liquid medium and
then washing the well twice, each time by adding 200 ll of
saline solution [0.9% NaCl (Merck)], and by aspirating
using a multichannel pipettor. The biofilms were incubated
for 24 h, in fresh nutrient medium (TSB) containing dap-
tomycin, linezolid, and rifampicin at the MIC and peak
serum concentrations (Table 1). At time 0 (before exposure
to antibiotics), the initial cellular concentration of biofilm
(*2 9 108 cells ml-1) was determined by CFU enumer-
ation. To this end, the planktonic cells were carefully
removed, and the biofilm-containing wells were washed
with 250 ll of saline solution. The wells were thoroughly
scraped with a cell scraper (zellschaber/24 cm) and resus-
pended in 1 mL of 0.9% NaCl, followed by centrifugation
for 10 min at 9,5009g and 4C. The pellet was resus-
pended in 0.9% NaCl and washed twice, followed by
sonication for 20 s at 22 W to homogenize the suspension.
Viable cells were determined by performing tenfold serial
dilutions in saline solution and plating in TSA. Colonies
were counted after 24 h incubation at 37C.
Crystal violet (CV) staining was used as indicator of
total biofilm biomass. After exposure to the treatment
agents, biofilms-containing wells were washed with 250 ll
of saline solution, and then 250 ll of methanol was added
to each well and allowed to react for 15 min. Afterward,
methanol was removed using a multichannel pipettor.
Then, 250 ll of CV 1% (v/v) was added (5 min). The wells
Table 1 MIC and peak serum concentrations of the antibiotics used
in this study
Antibiotic Peak serum
(lg ml-1)
S. epidermidis
9142 MIC
(lg ml-1)
S. epidermidis
1457 MIC
(lg ml-1)
DAP 95 [16] 0.25 0.50
LIN 18 [24] 1.00 1.00
RIF 10 [12] 0.015 0.015
DAP daptomycin, LIN linezolid, RIF rifampicin
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were washed with distilled water and finally, acetic acid
33% (v/v) was added. The absorbance was read on an
ELISA reader (Bio-Tek Instruments Inc., Vermont, USA)
at 570 nm.
The number of viable cells after antibiotic treatment was
assessed by CFU enumeration using the same protocol
described above. A control was obtained with biofilm cells
not exposed to the antibiotics tested. All the experiments
were carried out in triplicate and repeated three times.
Statistical Analysis
The data from all the assays were compared using one-way
analysis of variance (ANOVA), by applying Tukey’s test
with all the calculations carried out using SPSS software
(Statistical Package for the Social Sciences). Differences at
a confidence level of 95% were considered significant.
Results and Discussion
It is well-known that bacteria in biofilms are able to survive
in the presence of high concentrations of antimicrobial
agents. Bacterial survival in biofilms may be determined by
multiple factors, among which the presence of a surface
film composed of lipid components similar to those in
bacterial membranes that cover the biofilm and form a
barrier impairing the penetration of some antibiotics [2].
The inherent tolerance of biofilm cells and the antibiotic
resistance among pathogenic bacteria is a well-documented
phenomenon with severe consequences for the treatment of
nosocomial infections. Current antibiotics have been
proving inadequate to meet these challenges. Therefore,
new antibiotics are being developed aiming to replace
existing antibiotics that succumb to the rising tide of
resistance. In this decade, two antibacterials that belong to
new classes—daptomycin (a lipopeptide) and linezolid (an
oxazolidinone)—were approved and have offered new
options for the treatment of, e.g., complicated skin and skin
structure infections caused by resistant gram-positive
pathogens [17]. These facts triggered our interest in the
possible use of these two novel antibiotics in the treatment
of S. epidermidis biofilm-related infections.
Biofilms can be more than 1000 times more resistant to
antimicrobial agents, because of their inherent tolerance
[18]. In fact, a high antimicrobial effect against planktonic
cells is not a proof of high efficacy against the corre-
sponding cells in biofilm forms [19, 20]. Taking this into
consideration, the present study attempts to evaluate the in
vitro activity of these two antibiotics against S. epidermidis
biofilms, considering the potential use of these antimicro-
bial agents as possible alternatives to current antibiotics
(such as rifampicin), commonly used in the combat of
infections caused by S. epidermidis.
Table 1 presents the MIC and peak serum concentration
values of daptomycin, linezolid, and rifampicin used in this
study. The reductions in biofilm cells after 24 h of treat-
ment with the three antibiotics at MIC concentration are
presented in Fig. 1, where it is seen that, in such condition
neither the daptomycin nor the linezolid displayed an
antimicrobial effect against S. epidermidis biofilms. On the
other hand, rifampicin showed a statistically significant
(P \ 0.05) effect against both the strains of S. epidermidis
biofilm cells. However, although rifampicin was the most
active antibiotic tested, the CFU reduction promoted was
only slightly above 2 log10 and did not attain the 3 log10
threshold, to be considered bactericidal.
As described by several authors, antibiotics at concen-
trations of 102 to 104 times the MIC cause no killing effect
on bacteria in biofilm communities [21]. Taking this into
consideration, and with the aim of testing higher concen-
trations than MIC, we determined the susceptibility of
S. epidermidis biofilms to daptomycin, linezolid, and rif-
ampicin at the respective peak serum concentrations, since
such concentration is the highest level of drug that can be
obtained in the blood, usually following the administration
of multiple doses. In this case, rifampicin and daptomy-
cin showed a bactericidal effect against both strains of
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Fig. 1 Effects of rifampicin (RIF), daptomycin (DAP), and linezolid (LIN), at MIC and peak serum concentrations, on the number of biofilm
cells of S. epidermidis 9142 (a) and 1457 (b), after 24 h of treatment assessed by CFU enumeration. Error bars represent standard deviation
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S. epidermidis in biofilm form (P \ 0.05), while linezolid
effect was slightly smaller and more strain dependent
(Fig. 1).
Figure 2 depicts the effect of the antimicrobial agents
tested on total biofilm biomass of S. epidermidis biofilms,
assessed by CV staining. At MIC concentration, none of
the antibiotics caused any significant effect on biofilm
biomass of S. epidermidis biofilms. However, at peak
serum concentrations, the three antibiotics were able to
reduce biofilm biomass, with linezolid causing the highest
reduction (P \ 0.05) on total biofilm biomass, although not
much higher than the others.
This slightly higher reduction in total biofilm biomass
promoted by linezolid is expected to be because of a
decrease in the extracellular matrix, taking into account
that it was the agent that reduced the number of cells in a
lesser extent. The possible reduction in the extracelullar
matrix caused by linezolid may be a potential advantage,
since the biofilm structure become weaker, and the cells
present in the biofilm can be more susceptible to human
immune system and other antimicrobial agents. Therefore,
this mechanism of action can potentiate the inhibitory
effect of other antimicrobial agents, promoting synergistic
interactions. As an example, the combination of N-acetyl-
cysteine (NAC) and tigecycline was reported to work in
synergy [22]. A possible explanation to this increased-
effect may be due to the degradation of the extracellular
polysaccharide biofilm matrix by NAC, causing the bio-
film-associated cells more susceptible to the action of
tigecycline [22].
These results demonstrated that rifampicin and dapto-
mycin at peak serum had a very similar bactericidal effect
on S. epidermidis biofilms. However, taking into consid-
eration the rapid emergence of rifampicin resistance when
used as monotherapy [23], it that the use of daptomycin in
the treatment of S. epidermidis-related infections is more
feasible. This is supported by other researchers who
reported that, upon sometime of exposure, daptomycin was
the most active agent in eradicating S. aureus [23],
exhibiting very rapid bactericidal activity against this
pathogen [15]. As both S. aureus and S. epidermidis are
now among the major nosocomial pathogens, their similar
response to these antibiotics is very favorable from the
clinical point of view because it is possible to define a
relatively broad spectrum therapy.
The overall results obtained us led to conclude that
daptomycin at peak serum concentration was the most
active antimicrobial agent tested against S. epidermidis
biofilm cells. This novel antibiotic can be strongly con-
sidered as a potential alternative to rifampicin as mono-
therapy. However, regarding the therapeutic use in biofilm
control, future studies using animal models have to be per-
formed to determine the in vivo response of S. epidermidis
cells to this antimicrobial agent.
Although rifampicin also demonstrated to be highly
active against S. epidermidis biofilms either at MIC or PS
concentration, it should only be considered for enhanced
anti-Staphylococcal activity but in combination with other
antibiotics, to avoid the rapid emergence of resistance.
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